These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32110000)

  • 1. Adherence to Benzathine Penicillin G Secondary Prophylaxis and Its Determinants in Patients with Rheumatic Heart Disease at a Cardiac Center of an Ethiopian Tertiary Care Teaching Hospital.
    Mekonen KK; Yismaw MB; Abiye AA; Tadesse TA
    Patient Prefer Adherence; 2020; 14():343-352. PubMed ID: 32110000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease.
    Ketema EB; Gishen NZ; Hailu A; Leul A; Hadgu A; Hagos K; Berhane S; Tsega T; Page-Sharp M; Davis TM; Moore B; Batty KT; Carapetis J; Salman S; Manning L
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009399. PubMed ID: 34115748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to secondary prevention of rheumatic fever and rheumatic heart disease in young people: an 11-year retrospective study.
    Liaw J; Gorton S; Heal C; White A
    Aust N Z J Public Health; 2022 Dec; 46(6):758-763. PubMed ID: 35616403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study.
    Belay W; Dessie A; Ahmed H; Gedlu E; Mariyo A; Shehibo A; Tigabu Z; Aliyu MH; Soslow J
    BMC Cardiovasc Disord; 2022 Feb; 22(1):26. PubMed ID: 35109807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzathine penicillin adherence for secondary prophylaxis among patients affected with rheumatic heart disease attending Mulago Hospital.
    Musoke C; Mondo CK; Okello E; Zhang W; Kakande B; Nyakoojo W; Freers J
    Cardiovasc J Afr; 2013 May; 24(4):124-9. PubMed ID: 24217043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India.
    Arvind B; Saxena A; Kazi DS; Bolger AF
    Indian Heart J; 2021; 73(2):169-173. PubMed ID: 33865513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.
    Kado J; Salman S; Hla TK; Enkel S; Henderson R; Hand RM; Hort A; Page-Sharp M; Batty K; Moore BR; Bennett J; Anderson A; Carapetis J; Manning L
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0096223. PubMed ID: 37971244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review.
    Kevat PM; Reeves BM; Ruben AR; Gunnarsson R
    Curr Cardiol Rev; 2017; 13(2):155-166. PubMed ID: 28093988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.
    Hand RM; Salman S; Newall N; Vine J; Page-Sharp M; Bowen AC; Gray K; Baker A; Kado J; Joseph J; Marsh J; Ramsay J; Sika-Paotonu D; Batty KT; Manning L; Carapetis J
    J Antimicrob Chemother; 2019 Jul; 74(7):1984-1991. PubMed ID: 30989171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Hurts less, lasts longer"; a qualitative study on experiences of young people receiving high-dose subcutaneous injections of benzathine penicillin G to prevent rheumatic heart disease in New Zealand.
    Cooper J; Enkel SL; Moodley D; Dobinson H; Andersen E; Kado JH; Barr RK; Salman S; Baker MG; Carapetis JR; Manning L; Anderson A; Bennett J
    PLoS One; 2024; 19(5):e0302493. PubMed ID: 38743745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatic Heart Disease Patients' Adherence to Secondary Prophylaxis and Associated Factors at Hospitals in Jimma Zone, Southwest Ethiopia: A Multicenter Study.
    Adem A; Dukessa Gemechu T; Jarso H; Reta W
    Patient Prefer Adherence; 2020; 14():2399-2406. PubMed ID: 33304095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?
    Currie BJ
    Pediatrics; 1996 Jun; 97(6 Pt 2):989-91. PubMed ID: 8637788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis.
    Marantelli S; Hand R; Carapetis J; Beaton A; Wyber R
    Heart Asia; 2019; 11(2):e011191. PubMed ID: 31297163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.
    Page-Sharp M; Coward J; Moore BR; Salman S; Marshall L; Davis TME; Batty KT; Manning L
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG.
    Kassem AS; Zaher SR; Abou Shleib H; el-Kholy AG; Madkour AA; Kaplan EL
    Pediatrics; 1996 Jun; 97(6 Pt 2):992-5. PubMed ID: 8637789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective wellbeing among rheumatic heart disease patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: observational cross-sectional study.
    Tadele H; Ahmed H; Mintesnot H; Gedlu E; Guteta S; Yadeta D
    BMC Health Serv Res; 2021 Dec; 21(1):1354. PubMed ID: 34923975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of benzathine penicillin G: A multinational cross-sectional study.
    Hand RM; Senarathna SMDKG; Page-Sharp M; Gray K; Sika-Paotonu D; Sheel M; Chuang VTG; Martinez J; Luna G; Manning L; Wyber R; Carapetis JR; Batty KT
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00668. PubMed ID: 33090729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease.
    Barr RK; Barber BW; Tait JR; Landersdorfer CB; Salman S; Musk GC; Page-Sharp M; Batty KT; Kado J; Manning L; Carapetis JR; Boyd BJ
    Eur J Pharm Biopharm; 2023 Aug; 189():240-250. PubMed ID: 37354997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia.
    Kado J; Salman S; Hand R; O'Brien M; Ralph A; Bowen AC; Page-Sharp M; Batty KT; Dolman V; Francis JR; Carapetis J; Manning L
    J Antimicrob Chemother; 2022 Sep; 77(10):2679-2682. PubMed ID: 35822635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adequate adherence to benzathine penicillin secondary prophylaxis following the diagnosis of rheumatic heart disease by echocardiographic screening.
    Culliford-Semmens N; Tilton E; Webb R; Lennon D; Paku B; Malcolm J; French S; Blair N; Wilson N
    N Z Med J; 2017 Jun; 130(1457):50-57. PubMed ID: 28617789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.